Payment overview · 2025
General Payments
$651.35
28 reported records · 9 companies
Healthcare provider profile · identity verified
William H Heaton, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · FLORENCE, AL · NPI 1710049689
Verified facts
What the public records show
CMS Open Payments records show William H Heaton, MD received $651.35 in general payments during 2025 across 28 reported records.
Medtronic, Inc. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Verquvo.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1216 claims for Eliquis by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Verquvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1216 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$154.98 | 23.8% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $153.88 | 23.6% | 6 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $108.73 | 16.7% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.24 | 12.0% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.70 | 6.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.60 | 6.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.21 | 5.4% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.22 | 3.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.79 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $651.35 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $153.88 | 6 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $117.40 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $108.73 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $100.46 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $37.58 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.21 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1216 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1216 | 227 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1216 | 227 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 1216 | 227 |
| Furosemide | Furosemide | 597 | 150 |
| Amiodarone Hcl | Amiodarone Hcl | 561 | 158 |
| Labetalol Hcl | Labetalol Hcl | 525 | 117 |
| Spironolactone | Spironolactone | 465 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 413 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 114 |
| Clonidine | Clonidine | 394 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 385 | 95 |
| Carvedilol | Carvedilol | 340 | 90 |
| Pravastatin Sodium | Pravastatin Sodium | 333 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 82 |
| Entresto | Sacubitril/Valsartan | 317 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 284 | 97 |
| Farxiga | Dapagliflozin Propanediol | 270 | 53 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 268 | 66 |
| Ezetimibe | Ezetimibe | 259 | 65 |
| Jardiance | Empagliflozin | 249 | 53 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 242 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 240 | 65 |
| Valsartan | Valsartan | 219 | 70 |
| Xarelto | Rivaroxaban | 213 | 40 |
| Flecainide Acetate | Flecainide Acetate | 209 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 205 | 68 |
| Nitroglycerin | Nitroglycerin | 184 | 112 |
| Hydralazine Hcl | Hydralazine Hcl | 177 | 53 |
| Prasugrel Hcl | Prasugrel Hcl | 175 | 50 |
| Potassium Chloride | Potassium Chloride | 167 | 53 |
| Losartan Potassium | Losartan Potassium | 164 | 54 |
| Clonidine Hcl | Clonidine Hcl | 161 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 40 |
| Repatha Sureclick | Evolocumab | 157 | 22 |
| Lisinopril | Lisinopril | 152 | 50 |
| Ranolazine Er | Ranolazine | 151 | 35 |
| Nebivolol Hcl | Nebivolol Hcl | 146 | 45 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 141 | 43 |
| Warfarin Sodium | Warfarin Sodium | 117 | 26 |
| Brilinta | Ticagrelor | 116 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 114 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 31 |
| Allopurinol | Allopurinol | 99 | 23 |
| Irbesartan | Irbesartan | 92 | 26 |
| Fenofibrate | Fenofibrate | 90 | 22 |
| Simvastatin | Simvastatin | 86 | 23 |
| Vascepa | Icosapent Ethyl | 81 | 19 |
| Sotalol | Sotalol Hcl | 80 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 79 | 20 |
| Verquvo | Vericiguat | 77 | 15 |
| Famotidine | Famotidine | 73 | 17 |
| Omeprazole | Omeprazole | 72 | 20 |
| Digoxin | Digoxin | 71 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 16 |
| Ramipril | Ramipril | 56 | 14 |
| Nifedipine Er | Nifedipine | 55 | 15 |
| Eplerenone | Eplerenone | 54 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 15 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 51 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 11 |
| Metformin Hcl | Metformin Hcl | 39 | suppressed |
| Torsemide | Torsemide | 39 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Gabapentin | Gabapentin | 36 | 14 |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Kerendia | Finerenone | 34 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 32 | 12 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | 11 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Opsumit | Macitentan | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Droxidopa | Droxidopa | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $651.35 · 28 records | Medtronic, Inc. | AURORA EV-ICD MRI SURESCAN, ELIQUIS, Kerendia, LifeVest, MICRA, NEXLETOL, NURTEC ODT, REPATHA, VERQUVO, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error